Trump Administration Reclassifies Medical Marijuana Under Schedule III

Schedule III Status Ends 280E Tax Penalty

The reclassification removes the IRC §280E tax burden that's blocked cannabis operators from deducting ordinary business expenses since 1982. Under Schedule I classification, cannabis businesses paid effective federal tax rates exceeding 70 percent because §280E prohibits deductions for businesses trafficking in Schedule I or II controlled substances. Schedule III placement allows full deductibility of rent, payroll, marketing, and other operating costs against gross receipts.

The change applies to all state-licensed medical marijuana operators holding valid permits as of the effective date. Recreational cannabis remains Schedule I. It's still subject to §280E. Mixed-use operators must maintain separate books for medical and adult-use operations to claim deductions on the medical side—a strict reading of the final rule demands it.

DEA Finalizes Rule After 18-Month Comment Period

The DEA received 43,000 public comments during the notice-and-comment period that began in May 2024. The final rule adopts the August 2023 recommendation from the Department of Health and Human Services that cannabis has accepted medical use and lower abuse potential than Schedule I or II substances. Twelve state attorneys general petitioned for full descheduling; the DEA rejected them, stating that international treaty obligations under the 1961 Single Convention on Narcotic Drugs require some level of control.

The rule takes effect 60 days after Federal Register publication. That places the operative date in early August 2026. The DEA will issue guidance on state-program compliance requirements by July 15, 2026, according to the final rule's implementation timeline.

State-Licensed Operators Must Meet Federal Standards

Schedule III placement doesn't legalize cannabis under federal law but creates a safe harbor for operators meeting DEA registration and state-license requirements. All medical marijuana businesses must obtain DEA registration as manufacturers, distributors, or dispensers of Schedule III substances within 180 days. Registration fees range from $731 for dispensaries to $3,047 for cultivators, payable triennially.

State programs must demonstrate closed-loop tracking from seed to sale, background checks for all license holders, and product testing for potency and contaminants. As of June 2026, the DEA identified 38 state medical programs that meet federal standards. Five states—Alabama, Idaho, Nebraska, South Carolina, and Wyoming—remain non-compliant and ineligible for the safe harbor.

Banking and Interstate Commerce Remain Restricted

The reclassification doesn't resolve federal banking restrictions or authorize interstate transport of cannabis. The Bank Secrecy Act still classifies cannabis proceeds as potentially suspicious activity, and FDIC-insured institutions remain reluctant to service the sector without explicit statutory safe harbor. The SAFER Banking Act, which would create such protection, has stalled in the House since March 2025.

Interstate commerce remains prohibited under 21 U.S.C. §823(f), which limits Schedule III distribution to intrastate channels unless the DEA grants specific authorization. No such authorizations have been issued. Multi-state operators must continue to maintain separate cultivation and processing in each state, preventing economies of scale that exist in other regulated industries.

The tax relief is immediate and material, but the operational and capital-markets constraints that have defined the cannabis industry since 2014 remain largely intact.

Revenue Implications and What Operators Watch Next

The Joint Committee on Taxation estimates the 280E repeal will reduce federal revenue by $3.1 billion annually, with $18.7 billion in cumulative impact through 2031. That figure assumes no behavioral response; actual revenue loss may be lower if increased profitability drives higher taxable income. Treasury hasn't issued guidance on transition rules for operators with net operating losses carried forward under the old regime.

For full background on the administrative process that led to this rule, see the CannIntel topic hub on DEA rescheduling. Operators are now watching three variables: the July 15 DEA guidance on state-program compliance, Treasury's transition-rule interpretation, and any congressional action on SAFER Banking before the August recess. The HHS recommendation that triggered this process cited cannabidiol, THCA, and delta-9 THC as the primary cannabinoids with accepted medical use, but the final rule doesn't distinguish among cannabinoid profiles in its safe-harbor criteria.